144 related articles for article (PubMed ID: 17611960)
1. The neuroendocrine system and rheumatoid arthritis: insights from anti-tumor necrosis factor-alpha therapy.
Sternberg EM; Silverman MN; Cizza G
J Rheumatol; 2007 Jul; 34(7):1443-5. PubMed ID: 17611960
[No Abstract] [Full Text] [Related]
2. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
3. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis.
Atzeni F; Straub RH; Cutolo M; Sarzi-Puttini P
Ann N Y Acad Sci; 2010 Apr; 1193():179-81. PubMed ID: 20398027
[TBL] [Abstract][Full Text] [Related]
5. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems.
Härle P; Straub RH; Wiest R; Mayer A; Schölmerich J; Atzeni F; Carrabba M; Cutolo M; Sarzi-Puttini P
Ann Rheum Dis; 2006 Jan; 65(1):51-6. PubMed ID: 15941834
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
Nasonov EL
Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
[No Abstract] [Full Text] [Related]
7. [TNF antagonists in therapy of rheumatoid arthritis].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
[No Abstract] [Full Text] [Related]
8. [Hypothalamo-hypophyseal-adrenal function in rheumatoid arthritis treated with low-doses of corticoids].
Belmonte Serrano MA; Roig Escofet D; Gómez Sáez JM; Bonnín Lafuente MR
Med Clin (Barc); 1986 Sep; 87(7):275-9. PubMed ID: 3762252
[No Abstract] [Full Text] [Related]
9. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis.
Straub RH; Pongratz G; Cutolo M; Wijbrandts CA; Baeten D; Fleck M; Atzeni F; Grunke M; Kalden JR; Schölmerich J; Lorenz HM; Tak PP; Sarzi-Puttini P
Arthritis Rheum; 2008 Apr; 58(4):976-84. PubMed ID: 18383357
[TBL] [Abstract][Full Text] [Related]
10. [Tumor necrosis factor modulators in the treatment of rheumatoid arthritis].
Konttinen YT; Valleala H; Honkanen V; Törnwall J; Tensing EK; Sorsa T; Nordström D
Duodecim; 1999; 115(18):1969-76. PubMed ID: 11941814
[No Abstract] [Full Text] [Related]
11. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
[No Abstract] [Full Text] [Related]
13. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.
Gómez-Puerta JA; Sanmartí R; Rodríguez-Cros JR; Cañete JD
Ann Rheum Dis; 2004 Jul; 63(7):896. PubMed ID: 15194598
[No Abstract] [Full Text] [Related]
14. Anti-TNF-alpha therapies: they are all the same (aren't they?).
Mpofu S; Fatima F; Moots RJ
Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
[No Abstract] [Full Text] [Related]
15. [New drug treatments for rheumatoid arthritis].
Nordström DC; Konttinen YT
Duodecim; 2000; 116(11):1221-5. PubMed ID: 11989008
[No Abstract] [Full Text] [Related]
16. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
17. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
18. Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients.
Atzeni F; Straub RH; Cutolo M; Sarzi-Puttini P
Ann N Y Acad Sci; 2010 Apr; 1193():176-8. PubMed ID: 20398026
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
Segal B; Rhodus NL; Patel K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches.
Alten R; Wiebe E
Neuroimmunomodulation; 2015; 22(1-2):83-8. PubMed ID: 25228310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
